Funding for this research was provided by:
H. Lundbeck A/S (N/A)
Received: 20 November 2018
Accepted: 11 October 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: According to the EphMRA code of conduct, formal ethics approval was not required for this US market research study [CitationRef removed]. Participating psychiatrists gave digital written informed consent prior to starting the questionnaire. De-identified patient data were used and the need for patient consent was waived.
: Not applicable.
: CUC has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Bristol-Myers Squibb, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Merck, Neurocrine, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and ROVI. He received royalties from UpToDate and grant support from Janssen, and Takeda.TB and CB are employees of H. Lundbeck A/S.